Cargando…

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir

[Image: see text] The HIV-1 replication inhibitor dapivirine (DPV) is one of the most promising drug candidates being used in topical microbicide products for prevention of HIV-1 sexual transmission. To be able to block HIV-1 replication, DPV must have access to the viral reverse transcriptase enzym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akil, Ayman, Devlin, Brid, Cost, Marilyn, Rohan, Lisa Cencia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018102/ https://www.ncbi.nlm.nih.gov/pubmed/24693866 http://dx.doi.org/10.1021/mp4007024

Ejemplares similares

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole
por: Valicherla, Guru Raghavendra, et al.
Publicado: (2021)

Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel
por: Li, Jing, et al.
Publicado: (2019)

Design of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis
por: Yang, Haitao, et al.
Publicado: (2019)

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2022)

Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
por: Dallal Bashi, Yahya H., et al.
Publicado: (2021)

Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance
por: Murphy, Diarmaid J., et al.
Publicado: (2021)

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States
por: Liu, Albert Y, et al.
Publicado: (2021)

Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
por: Kusemererwa, Sylvia, et al.
Publicado: (2022)

In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel
por: Murphy, Diarmaid J., et al.
Publicado: (2022)

Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial
por: Brown, Elizabeth R, et al.
Publicado: (2020)

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
por: Zheng, Ruohui, et al.
Publicado: (2022)

Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls
por: Farr Zuend, Christina, et al.
Publicado: (2021)

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
por: Glaubius, Robert, et al.
Publicado: (2019)

Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
por: Dezzutti, Charlene S., et al.
Publicado: (2016)

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention
por: Palanee-Phillips, Thesla, et al.
Publicado: (2015)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
por: Mayo, Ashley J., et al.
Publicado: (2021)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma
por: Liu, Weiwen, et al.
Publicado: (2018)

Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial
por: Palanee-Phillips, Thesla, et al.
Publicado: (2018)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
por: Bhavaraju, Neeraja, et al.
Publicado: (2021)

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine
por: Wang, Scarlet Xiaoyan, et al.
Publicado: (2016)

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
por: Nel, Annalene, et al.
Publicado: (2016)

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
por: Parikh, Urvi M., et al.
Publicado: (2021)

Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis
por: Young, Alinda M., et al.
Publicado: (2023)

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study
por: Garcia, Morgan, et al.
Publicado: (2021)

HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania
por: Tubert, Julia, et al.
Publicado: (2021)

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
por: Ngure, Kenneth, et al.
Publicado: (2023)

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings
por: Thurman, Andrea Ries, et al.
Publicado: (2019)

Progress in antiretroviral drug delivery using nanotechnology
por: Mallipeddi, Rama, et al.
Publicado: (2010)

Label-free analysis of tenofovir delivery to vaginal tissue using co-registered confocal Raman spectroscopy and optical coherence tomography
por: Chuchuen, Oranat, et al.
Publicado: (2017)

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring
por: Thurman, Andrea R., et al.
Publicado: (2022)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates
por: Patel, Sravan Kumar, et al.
Publicado: (2023)

In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide
por: Rohan, Lisa C., et al.
Publicado: (2010)

Release of Tenofovir from Carrageenan-Based Vaginal Suppositories
por: Zaveri, Toral, et al.
Publicado: (2014)

Silicon Oxycarbide Porous Particles and Film Coating as Strategies for Tenofovir Controlled Release in Vaginal Tablets for HIV Prevention
por: Martín-Illana, Araceli, et al.
Publicado: (2022)

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments
por: Hendrix, Craig W., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_l15ocfntso0v465f03aqu4h3sg